Trisubstituted Imidazoles as Mycobacterium tuberculosis Glutamine Synthetase Inhibitors
Journal of Medicinal Chemistry2012Vol. 55(6), pp. 2894–2898
Citations Over TimeTop 11% of 2012 papers
Johan Gising, Mikael Nilsson, Luke R. Odell, Samir Yahiaoui, Martin Lindh, Harini Iyer, A M Sinha, B. R. Srinivasa, Mats Larhed, Sherry L. Mowbray, Anders Karlén
Abstract
Mycobacterium tuberculosis glutamine synthetase (MtGS) is a promising target for antituberculosis drug discovery. In a recent high-throughput screening study we identified several classes of MtGS inhibitors targeting the ATP-binding site. We now explore one of these classes, the 2-tert-butyl-4,5-diarylimidazoles, and present the design, synthesis, and X-ray crystallographic studies leading to the identification of MtGS inhibitors with submicromolar IC(50) values and promising antituberculosis MIC values.
Related Papers
- → Drug Discovery Goes Three-Dimensional: Goodbye to Flat High-Throughput Screening?(2015)77 cited
- → ARQiv-HTS, a versatile whole-organism screening platform enabling in vivo drug discovery at high-throughput rates(2016)50 cited
- → High-Throughput and In Silico Screening in Drug Discovery(2017)10 cited
- → Biological Function of the Ammonia‐Induced Inactivation of Glutamine Synthetase in Escherichia coli(1972)54 cited
- → Factors affecting the production of glutamine in cultured mouse cells(1971)36 cited